Advanced search
Publication Cover
Hematology Volume 27, 2022 - Issue 1
Submit an article Journal homepage
5,066
Views
5
CrossRef citations to date
0
Altmetric
Rapid Communication

Outcomes of anti-CD38 isatuximab plus pomalidomide and dexamethasone in five relapsed myeloma patients with prior exposure to anti-C38 daratumumab: case series

Faouzi Djebbaria Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UKCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-9578-7632
ORCID Icon,
Matt Poyntonb Royal Berkshire Hospital, Reading, UK
,
Gina Sanghac Milton Keynes Hospital, Milton Keynes, UK
,
Laura Andersond Royal United Hospital Bath, Bath, UK
,
Rebecca Maddamse Poole Hospital, Poole, UK
,
Toby A. Eyrea Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
,
Grant Vallancea Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
,
Supratik Basuf The Royal Wolverhampton NHS Trust, Wolverhampton, UK;g Faculty of Science and Engineering, University of Wolverhampton, Wolverhampton, UK;h West Midlands Research Consortium (WMRC), West Midlands, UK
&
Karthik Ramasamya Department of Clinical Haematology, Oxford University Hospitals NHS Foundation Trust, Oxford, UK
 show all
Pages 204-207 | Published online: 08 Feb 2022

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Sigrid De Wilde, Laurent Plawny & Guy Berchem. (2023) Real-world experience with isatuximab in the treatment of relapsed-refractory multiple myeloma: a case series from the Grand Duchy of Luxembourg. Hematology 28:1.
Read now

Articles from other publishers (4)

Alexander Lesokhin, Richard LeBlanc, Meletios A. Dimopoulos, Marcelo Capra, Carmelo Carlo‐Stella, Lionel Karlin, Jean‐Francois Castilloux, Peter Forsberg, Gurdeep Parmar, Axel Tosikyan, Ludek Pour, Vincent Ribrag, Rossella Ribolla, Al‐Ola Abdallah, Nadia Le Roux, Liyan Dong, Helgi van de Velde, Laurent Mayrargue, Lucie Lépine, Sandrine Macé & Philippe Moreau. (2023) Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study. Cancer Medicine.
Crossref
. (2023) Antineoplastics. Reactions Weekly 1940:1, pages 66-66.
Crossref
Felipe de Arriba de la Fuente, Carmen Montes Gaisán & Javier de la Rubia Comos. (2022) How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma. Cancers 15:1, pages 155.
Crossref
Fei Shen & Weidong Shen. (2022) Isatuximab in the Treatment of Multiple Myeloma: A Review and Comparison With Daratumumab. Technology in Cancer Research & Treatment 21, pages 153303382211065.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.